Mesothelioma is hard to treat and usually not curable, but treatments can extend life, ease symptoms, and sometimes lead to long-term survival, especially with early diagnosis and doctors who treat this disease. Understanding what each treatment involves, and how doctors decide between them, can help patients and families feel more prepared for the conversations ahead.
If you or a loved one has been diagnosed with mesothelioma, Braver Law can help you understand your legal options while your medical team builds a treatment plan. 800-672-7181.
Is Mesothelioma Curable?
Mesothelioma is not considered curable for most patients. It is typically diagnosed after the cancer has already progressed, since early symptoms are often mild or mistaken for less serious conditions. That said, “not curable” does not mean “not treatable.” Many patients respond well to treatment, and a meaningful number live significantly longer than average survival statistics suggest, particularly those diagnosed at an earlier stage, with a more favorable cell type, and treated with a combination of therapies.
The goal of treatment for most patients is to slow the cancer’s progression, manage symptoms, and extend life as much as possible, while a smaller group of patients with localized, early-stage disease may be eligible for treatment aimed at removing all detectable cancer.
Factors That Determine Treatment Options
Not every patient is a candidate for every treatment. Doctors typically consider several factors before recommending a plan, and understanding these factors can help patients and families ask more informed questions during treatment planning appointments:
- Stage at diagnosis. Earlier-stage tumors are more likely to be surgically removable, while later-stage disease usually shifts treatment toward systemic therapies aimed at controlling rather than eliminating the cancer.
- Cell type. Epithelioid mesothelioma usually responds better to surgery and chemotherapy than sarcomatoid or biphasic tumors, though newer immunotherapy has helped even the harder-to-treat cell types.
- Tumor location. Pleural mesothelioma and peritoneal mesothelioma are treated differently, with peritoneal disease often responding well to a surgical and chemotherapy combination that is not typically used for pleural cases.
- Age and overall health. Intensive treatments like surgery carry real risks, and patients need to be healthy enough for them. Many mesothelioma patients are diagnosed in their late 60s or 70s, sometimes with other health conditions, which can limit surgical eligibility even when the tumor itself is in an early stage.
- Patient preference. Some patients choose intensive treatment to extend life as long as possible, while others focus on quality of life and symptom relief. Both are valid approaches, and oncologists should discuss the tradeoffs of each honestly rather than steering a patient toward one path.
Surgery
For early-stage mesothelioma, surgery may offer the most direct way to remove as much cancer as possible. The specific procedure depends on tumor location.
For pleural mesothelioma, the two main surgical approaches are pleurectomy with decortication (P/D), which removes the pleural lining and any visible tumor while preserving the lung, and extrapleural pneumonectomy (EPP), a more extensive procedure that removes the affected lung along with the pleura, diaphragm, and pericardium. P/D generally has fewer complications and a shorter recovery, while EPP is sometimes used when the cancer has spread more within the chest, though its use has declined.
For peritoneal mesothelioma, the standard surgical approach is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Surgeons remove as much visible tumor as possible from the abdominal cavity, then apply heated chemotherapy directly to the area to destroy remaining cancer cells. This approach has produced notably better outcomes than surgery alone, with some high-volume treatment centers reporting 5-year survival rates well above the historical average for peritoneal disease in appropriately selected patients.
Surgery is rarely curative on its own and is usually combined with chemotherapy or radiation before or after the procedure, an approach generally referred to as multimodal therapy.
Chemotherapy
Chemotherapy remains a core part of mesothelioma treatment, whether used alone, before surgery to shrink a tumor, after surgery to target remaining cancer cells, or in combination with immunotherapy. The standard chemotherapy for mesothelioma combines pemetrexed with a platinum drug such as cisplatin or carboplatin, and it has been the main first-line treatment for many years.
Chemotherapy can cause significant side effects, including fatigue, nausea, hair loss, and a weakened immune system that increases vulnerability to infection, and tolerance varies considerably from patient to patient. Oncologists typically weigh a patient’s age, kidney function, and overall health when determining dosage and the number of treatment cycles, and some patients need adjustments partway through treatment if side effects become difficult to manage.
In recent years, some oncologists have also begun combining chemotherapy with immunotherapy as a first-line approach for eligible patients, based on trial data showing improved outcomes over chemotherapy given on its own.
Radiation Therapy
Radiation therapy is most often used after surgery to target any remaining cancer cells in the treated area, or as a palliative treatment to reduce pain and improve breathing in patients with more advanced disease. Modern techniques such as intensity-modulated radiation therapy (IMRT) allow doctors to target tumors more precisely while limiting damage to surrounding healthy tissue, which has made radiation a more tolerable option than it was in the past. Radiation is generally not used as a standalone treatment aimed at curing mesothelioma, since the disease tends to spread across a wide surface area that is difficult to treat with radiation alone.
Immunotherapy
Immunotherapy has meaningfully changed the treatment landscape for mesothelioma over the past several years. Rather than attacking cancer cells directly the way chemotherapy does, immunotherapy works by helping a patient’s own immune system recognize and attack cancer cells more effectively.
The most significant development has been the combination of nivolumab and ipilimumab, two checkpoint inhibitor drugs that received FDA approval as a first-line treatment for unresectable pleural mesothelioma in 2020, based on results from the CheckMate-743 clinical trial. Long-term follow-up data has continued to show a meaningful survival benefit for this combination compared to chemotherapy alone, with the benefit appearing particularly notable among patients with sarcomatoid and biphasic cell types, who historically had few effective treatment options.
A second immunotherapy approach, combining pembrolizumab with pemetrexed and platinum-based chemotherapy, became available as an additional first-line option more recently, giving oncologists more than one evidence-based immunotherapy regimen to choose from depending on a patient’s specific situation.
Immunotherapy is not effective for every patient, and side effects, while generally different from traditional chemotherapy, can still be significant, including immune-related reactions that require careful monitoring. An oncologist who treats mesothelioma can tell you whether immunotherapy is right for you.
Clinical Trials
Because mesothelioma is rare and continues to have limited treatment options compared to more common cancers, clinical trials play an important role in expanding what is available to patients, particularly those who have exhausted standard treatments or who have a cell type that responds poorly to existing therapies. Current areas of research include new immunotherapy combinations, cancer vaccines, CAR T-cell therapy, and targeted drugs aimed at specific genetic mutations found in some mesothelioma tumors.
Not every patient qualifies for every trial, since eligibility criteria vary based on prior treatment history, overall health, and specific tumor characteristics. Some trials are open only to patients who have not yet received any treatment, while others are designed specifically for patients whose cancer has progressed despite standard therapy.
Working with a mesothelioma specialist at a cancer center with an active research program is generally the most reliable way to learn about trials that a specific patient may qualify for, since these specialists tend to be more aware of newly opened trials and less common eligibility pathways than a general oncologist might be.
Palliative Care
For patients whose cancer is too advanced for treatment aimed at a cure or longer life, or who choose comfort over intensive treatment, palliative care manages pain, breathing problems, and other symptoms. This can include medication to manage pain and shortness of breath, procedures to drain fluid buildup around the lungs or abdomen, and support from specialists trained specifically in symptom management for serious illness.
Palliative care is not the same as giving up on treatment. Many patients receive palliative care alongside chemotherapy, immunotherapy, or radiation, using it specifically to manage side effects and symptoms while other treatments continue, and some patients transition to palliative care as their primary focus only after other treatment options have been fully explored.
Finding the Right Specialists and Treatment Centers
Because mesothelioma is uncommon, many general oncologists see very few cases over the course of their careers. Patients treated by doctors who focus on mesothelioma, often at cancer centers with thoracic oncology or peritoneal programs, may have more treatment options, including clinical trials. Finding the right doctor and the right treatment center can meaningfully affect both quality of life and survival outlook, and researching mesothelioma specialists and treatment centers early after diagnosis is one of the most useful steps a patient or family can take.
What to Do After Choosing a Treatment Path
Regardless of which treatment approach a patient and their medical team decide on, most mesothelioma patients and their families also need to think about the financial side of a diagnosis. Because mesothelioma is caused almost exclusively by asbestos exposure, patients may be eligible for compensation through a personal injury claim, a settlement, an asbestos bankruptcy trust fund, or VA benefits if the exposure occurred during military service. That compensation can help cover the cost of treatment, travel to cancer centers, and lost income during a difficult time.
At Braver Law, our team helps clients pursue this compensation with no upfront costs.
Frequently Asked Questions
Is there a cure for mesothelioma?
What is the most effective mesothelioma treatment?
How has immunotherapy changed mesothelioma treatment?
Are clinical trials a good option for mesothelioma patients?
Does treatment differ for peritoneal mesothelioma compared to pleural mesothelioma?
Speak With Our Mesothelioma Team Today
If you or a loved one has been diagnosed with mesothelioma, contact Braver Law for a free, no-obligation case review. We can help you see if you may be eligible for compensation. No Fee Unless We Recover for You.
GET A FREE CASE REVIEW